Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Biologics Post-Market Activities

Biologics Post-Market Activities

                        CBER’s Sentinel Program
          Postmarketing Clinical Trials


                        Lot Release Home
          Vaccines, Blood & Biologics
          Guidance, Compliance & Regulatory Information (Biologics)
          Biologics Post-Market Activities
          Postmarketing Clinical TrialsBiologics Post-Market Activities Postmarketing Clinical Trials
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintPostmarketing study commitments are studies required of or agreed to by a sponsor that are conducted after FDA has approved a product for marketing. FDA uses postmarketing study commitments to gather additional information about a product's safety, efficacy, or optimal use. Agreements with sponsors to conduct postmarketing studies can be reached either before or after FDA has granted approval to a sponsor to market a product.

The Food and Drug Administration Modernization Act of 1997 (FDAMA) amended the Food, Drug and Cosmetic Act by adding a new section 506B (21 U.S.C. 356b). This section provides additional authority for monitoring the progress of postmarketing studies that drug and biologic applicants have agreed to conduct. Congress enacted this section in response to concerns expressed by the Food and Drug Administration and the public about the timeliness of completing postmarketing studies and about the need to update drug labeling with information obtained from such studies.

This provision requires sponsors of approved drugs and biologics to report to FDA annually on the progress of their postmarketing study commitments.

In addition, FDA must publish annually in the Federal Register a report that provides information on the status of postmarketing studies that sponsors have agreed to conduct and for which annual reports have been submitted.

FDA also agreed to make basic information about the status of each postmarketing study commitment available to the public on the Internet.

The postmarketing study information includes the basic information the FDA committed to make available to the public. Proprietary information is not included.

The list will be updated quarterly (in April, July, October, and January). New commitments and status updates for existing commitments will be added to the list with the updates.

Questions or comments may be sent to the Postmarketing Study Commitment Coordinator at pmcweb@cder.fda.gov.

Related Information

Postmarketing Reports
	Final Rule: Postmarketing Studies for Approved Human Drug and Licensed
	Reports on the Status of Postmarketing Study Commitments - Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997
	Postmarket Requirements and Commitments Search

                                                                                  Content current as of:
      03/29/2019
              
              
Regulated Product(s)
		 BiologicsTopic(s)
			  Application & ApprovalsBiologics Post-Market Activities

          
                        CBER’s Sentinel Program
          Postmarketing Clinical Trials


                        Lot Release
 Subscribe for CBER Updates
                        Get e-mail updates on What’s New at CBER!
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop